Barbier P, Colelli A, Maggio R, Bravi D, Corsini G U
Institute of Pharmacology, School of Medicine, University of Pisa, Italy.
J Neural Transm (Vienna). 1997;104(8-9):867-74. doi: 10.1007/BF01285554.
Pergolide is an ergotamine derivative with potent D1 and D2 receptor activity. In this study we showed that pergolide binds tightly to dopamine D2 short receptors, as indicated by the long period of occupancy of the receptors after washing. Furthermore, pergolide induces receptor internalization to a larger extent than dopamine, seeing that no recycling of the receptors to the plasma membrane was observed for either agonist. The dissociation of pergolide from dopamine receptors occurs during the endocytotic process, leaving the receptors accessible to [3H]methylspiperone. Pergolide is a lipophilic compound that can reach and compete with [3H]methylspiperone for binding to sequestered receptors. If internalized receptors are still a target for drug action, pergolide could be a suitable compound of therapeutic interest in cases where receptor sequestration could prevent dopamine efficacy, as in levodopa therapy.
培高利特是一种具有强效D1和D2受体活性的麦角胺衍生物。在本研究中,我们发现培高利特与多巴胺D2短受体紧密结合,这从洗涤后受体的长时间占据情况可以看出。此外,培高利特比多巴胺更能诱导受体内化,因为对于这两种激动剂,均未观察到受体再循环至质膜。培高利特与多巴胺受体的解离发生在内吞过程中,使得受体可被[3H]甲基螺哌隆结合。培高利特是一种亲脂性化合物,它能够到达并与[3H]甲基螺哌隆竞争结合被隔离的受体。如果内化的受体仍是药物作用的靶点,那么在受体隔离可能会妨碍多巴胺疗效的情况下,如左旋多巴治疗,培高利特可能是一种具有治疗意义的合适化合物。